Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway

A. M. Martelli, C. Evangelisti, W. Chappell, S. L. Abrams, J. Bäsecke, F. Stivala, M. Donia, P. Fagone, F. Nicoletti, M. Libra, V. Ruvolo, P. Ruvolo, C. R. Kempf, L. S. Steelman, J. A. McCubrey

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is often implicated in sensitivity and resistance to therapy. Dysregulated signaling through the PI3K/PTEN/Akt/mTOR pathway is often the result of genetic alterations in critical components in this pathway as well as mutations at upstream growth factor receptors. Furthermore, this pathway is activated by autocrine transformation mechanisms. PTEN is a critical tumor suppressor gene and its dysregulation results in the activation of Akt. PTEN is often mutated, silenced and is often haploinsufficient. The mTOR complex1 (mTORC1) regulates the assembly of the eukaryotic initiation factor4F complex, which is critical for the translation of mRNAs that are important for cell growth, prevention of apoptosis and transformation. These mRNAs have long 5′-untranslated regions that are GC rich, rendering them difficult to translate. Elevated mTORC1 activity promotes the translation of these mRNAs via the phosphorylation of 4E-BP1. mTORC1 is a target of rapamycin and novel active-site inhibitors that directly target the TOR kinase activity. Although rapamycin and novel rapalogs are usually cytostatic and not cytotoxic for leukemic cells, novel inhibitors that target the kinase activities of PI3K and mTOR may prove more effective for leukemia therapy.

Original languageEnglish
Pages (from-to)1064-1079
Number of pages16
JournalLeukemia
Volume25
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

1-Phosphatidylinositol 4-Kinase
Sirolimus
Leukemia
Protein Biosynthesis
Therapeutics
TOR Serine-Threonine Kinases
Growth Factor Receptors
5' Untranslated Regions
Cytostatic Agents
Growth
Tumor Suppressor Genes
Phosphoric Monoester Hydrolases
Catalytic Domain
Phosphotransferases
Chromosomes
Phosphorylation
Apoptosis
Messenger RNA
Mutation

Keywords

  • mTOR
  • PI3K
  • resistance
  • sensitivity
  • therapy
  • translation

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Martelli, A. M., Evangelisti, C., Chappell, W., Abrams, S. L., Bäsecke, J., Stivala, F., ... McCubrey, J. A. (2011). Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia, 25(7), 1064-1079. https://doi.org/10.1038/leu.2011.46

Targeting the translational apparatus to improve leukemia therapy : Roles of the PI3K/PTEN/Akt/mTOR pathway. / Martelli, A. M.; Evangelisti, C.; Chappell, W.; Abrams, S. L.; Bäsecke, J.; Stivala, F.; Donia, M.; Fagone, P.; Nicoletti, F.; Libra, M.; Ruvolo, V.; Ruvolo, P.; Kempf, C. R.; Steelman, L. S.; McCubrey, J. A.

In: Leukemia, Vol. 25, No. 7, 07.2011, p. 1064-1079.

Research output: Contribution to journalArticle

Martelli, AM, Evangelisti, C, Chappell, W, Abrams, SL, Bäsecke, J, Stivala, F, Donia, M, Fagone, P, Nicoletti, F, Libra, M, Ruvolo, V, Ruvolo, P, Kempf, CR, Steelman, LS & McCubrey, JA 2011, 'Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway', Leukemia, vol. 25, no. 7, pp. 1064-1079. https://doi.org/10.1038/leu.2011.46
Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia. 2011 Jul;25(7):1064-1079. https://doi.org/10.1038/leu.2011.46
Martelli, A. M. ; Evangelisti, C. ; Chappell, W. ; Abrams, S. L. ; Bäsecke, J. ; Stivala, F. ; Donia, M. ; Fagone, P. ; Nicoletti, F. ; Libra, M. ; Ruvolo, V. ; Ruvolo, P. ; Kempf, C. R. ; Steelman, L. S. ; McCubrey, J. A. / Targeting the translational apparatus to improve leukemia therapy : Roles of the PI3K/PTEN/Akt/mTOR pathway. In: Leukemia. 2011 ; Vol. 25, No. 7. pp. 1064-1079.
@article{fb907f1463914d008e01ef4a8a8473e6,
title = "Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway",
abstract = "It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is often implicated in sensitivity and resistance to therapy. Dysregulated signaling through the PI3K/PTEN/Akt/mTOR pathway is often the result of genetic alterations in critical components in this pathway as well as mutations at upstream growth factor receptors. Furthermore, this pathway is activated by autocrine transformation mechanisms. PTEN is a critical tumor suppressor gene and its dysregulation results in the activation of Akt. PTEN is often mutated, silenced and is often haploinsufficient. The mTOR complex1 (mTORC1) regulates the assembly of the eukaryotic initiation factor4F complex, which is critical for the translation of mRNAs that are important for cell growth, prevention of apoptosis and transformation. These mRNAs have long 5′-untranslated regions that are GC rich, rendering them difficult to translate. Elevated mTORC1 activity promotes the translation of these mRNAs via the phosphorylation of 4E-BP1. mTORC1 is a target of rapamycin and novel active-site inhibitors that directly target the TOR kinase activity. Although rapamycin and novel rapalogs are usually cytostatic and not cytotoxic for leukemic cells, novel inhibitors that target the kinase activities of PI3K and mTOR may prove more effective for leukemia therapy.",
keywords = "mTOR, PI3K, resistance, sensitivity, therapy, translation",
author = "Martelli, {A. M.} and C. Evangelisti and W. Chappell and Abrams, {S. L.} and J. B{\"a}secke and F. Stivala and M. Donia and P. Fagone and F. Nicoletti and M. Libra and V. Ruvolo and P. Ruvolo and Kempf, {C. R.} and Steelman, {L. S.} and McCubrey, {J. A.}",
year = "2011",
month = "7",
doi = "10.1038/leu.2011.46",
language = "English",
volume = "25",
pages = "1064--1079",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Targeting the translational apparatus to improve leukemia therapy

T2 - Roles of the PI3K/PTEN/Akt/mTOR pathway

AU - Martelli, A. M.

AU - Evangelisti, C.

AU - Chappell, W.

AU - Abrams, S. L.

AU - Bäsecke, J.

AU - Stivala, F.

AU - Donia, M.

AU - Fagone, P.

AU - Nicoletti, F.

AU - Libra, M.

AU - Ruvolo, V.

AU - Ruvolo, P.

AU - Kempf, C. R.

AU - Steelman, L. S.

AU - McCubrey, J. A.

PY - 2011/7

Y1 - 2011/7

N2 - It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is often implicated in sensitivity and resistance to therapy. Dysregulated signaling through the PI3K/PTEN/Akt/mTOR pathway is often the result of genetic alterations in critical components in this pathway as well as mutations at upstream growth factor receptors. Furthermore, this pathway is activated by autocrine transformation mechanisms. PTEN is a critical tumor suppressor gene and its dysregulation results in the activation of Akt. PTEN is often mutated, silenced and is often haploinsufficient. The mTOR complex1 (mTORC1) regulates the assembly of the eukaryotic initiation factor4F complex, which is critical for the translation of mRNAs that are important for cell growth, prevention of apoptosis and transformation. These mRNAs have long 5′-untranslated regions that are GC rich, rendering them difficult to translate. Elevated mTORC1 activity promotes the translation of these mRNAs via the phosphorylation of 4E-BP1. mTORC1 is a target of rapamycin and novel active-site inhibitors that directly target the TOR kinase activity. Although rapamycin and novel rapalogs are usually cytostatic and not cytotoxic for leukemic cells, novel inhibitors that target the kinase activities of PI3K and mTOR may prove more effective for leukemia therapy.

AB - It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is often implicated in sensitivity and resistance to therapy. Dysregulated signaling through the PI3K/PTEN/Akt/mTOR pathway is often the result of genetic alterations in critical components in this pathway as well as mutations at upstream growth factor receptors. Furthermore, this pathway is activated by autocrine transformation mechanisms. PTEN is a critical tumor suppressor gene and its dysregulation results in the activation of Akt. PTEN is often mutated, silenced and is often haploinsufficient. The mTOR complex1 (mTORC1) regulates the assembly of the eukaryotic initiation factor4F complex, which is critical for the translation of mRNAs that are important for cell growth, prevention of apoptosis and transformation. These mRNAs have long 5′-untranslated regions that are GC rich, rendering them difficult to translate. Elevated mTORC1 activity promotes the translation of these mRNAs via the phosphorylation of 4E-BP1. mTORC1 is a target of rapamycin and novel active-site inhibitors that directly target the TOR kinase activity. Although rapamycin and novel rapalogs are usually cytostatic and not cytotoxic for leukemic cells, novel inhibitors that target the kinase activities of PI3K and mTOR may prove more effective for leukemia therapy.

KW - mTOR

KW - PI3K

KW - resistance

KW - sensitivity

KW - therapy

KW - translation

UR - http://www.scopus.com/inward/record.url?scp=79960271775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960271775&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.46

DO - 10.1038/leu.2011.46

M3 - Article

C2 - 21436840

AN - SCOPUS:79960271775

VL - 25

SP - 1064

EP - 1079

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -